{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&sessionNumber=2&min-date=2016-01-22&min-ddpModified=2015-02-08T23%3A26%3A13.160Z&min-ddpCreated=2016-10-12T22%3A44%3A03.023Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&sessionNumber=2&min-date=2016-01-22&min-ddpModified=2015-02-08T23%3A26%3A13.160Z&min-ddpCreated=2016-10-12T22%3A44%3A03.023Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&sessionNumber=2&min-date=2016-01-22&min-ddpModified=2015-02-08T23%3A26%3A13.160Z&min-ddpCreated=2016-10-12T22%3A44%3A03.023Z&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&_page=0&sessionNumber=2&min-date=2016-01-22&min-ddpModified=2015-02-08T23%3A26%3A13.160Z&min-ddpCreated=2016-10-12T22%3A44%3A03.023Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&sessionNumber=2&min-date=2016-01-22&min-ddpModified=2015-02-08T23%3A26%3A13.160Z&min-ddpCreated=2016-10-12T22%3A44%3A03.023Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&sessionNumber=2&min-date=2016-01-22&min-ddpModified=2015-02-08T23%3A26%3A13.160Z&min-ddpCreated=2016-10-12T22%3A44%3A03.023Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1459977", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459977/answer", "answerText" : {"_value" : "
Any public announcement on the procurement of therapeutics would be made after an agreement is reached with companies, as this information is commercially sensitive. The Department continues to examine the potential introduction of prophylaxis, which includes deployment and administration processes. Any such therapeutic treatment must provide evidence that it is clinically cost-effective, does not contribute to the generation of new variants and demonstrate sufficient efficacy against Omicron and new variants.<\/p>
The Therapeutics Clinical Review Panel is providing advice on the most appropriate patient cohorts for new COVID-19 therapeutics, including preventive treatments such as Evusheld. Final clinical policies and eligibility would be determined by the National Health Service and the devolved administrations.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4447", "label" : {"_value" : "Biography information for Maggie Throup"} } , "answeringMemberConstituency" : {"_value" : "Erewash"} , "answeringMemberPrinted" : {"_value" : "Maggie Throup"} , "dateOfAnswer" : {"_value" : "2022-04-28", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "158929"} , {"_value" : "159058"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2022-04-28T08:34:34.913Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2022-04-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Tixagevimab/cilgavimab"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 March 2022 to Question 141960 on Evusheld, what progress has been made on the assessment of Evusheld for treating immunocompromised patients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"} } , "tablingMemberConstituency" : {"_value" : "Crawley"} , "tablingMemberPrinted" : [{"_value" : "Henry Smith"} ], "uin" : "158928"} , {"_about" : "http://data.parliament.uk/resources/1459978", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459978/answer", "answerText" : {"_value" : "
Any public announcement on the procurement of therapeutics would be made after an agreement is reached with companies, as this information is commercially sensitive. The Department continues to examine the potential introduction of prophylaxis, which includes deployment and administration processes. Any such therapeutic treatment must provide evidence that it is clinically cost-effective, does not contribute to the generation of new variants and demonstrate sufficient efficacy against Omicron and new variants.<\/p>
The Therapeutics Clinical Review Panel is providing advice on the most appropriate patient cohorts for new COVID-19 therapeutics, including preventive treatments such as Evusheld. Final clinical policies and eligibility would be determined by the National Health Service and the devolved administrations.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4447", "label" : {"_value" : "Biography information for Maggie Throup"} } , "answeringMemberConstituency" : {"_value" : "Erewash"} , "answeringMemberPrinted" : {"_value" : "Maggie Throup"} , "dateOfAnswer" : {"_value" : "2022-04-28", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "158928"} , {"_value" : "159058"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2022-04-28T08:34:34.947Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2022-04-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Tixagevimab/cilgavimab"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 March 2022 to Question 141960 on Evusheld, when patients in the UK will have access to Evusheld as a preventative treatment for covid-19.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"} } , "tablingMemberConstituency" : {"_value" : "Crawley"} , "tablingMemberPrinted" : [{"_value" : "Henry Smith"} ], "uin" : "158929"} , {"_about" : "http://data.parliament.uk/resources/1459979", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459979/answer", "answerText" : {"_value" : "
It has not proved possible to respond to the hon. Member in the time available before Prorogation.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4447", "label" : {"_value" : "Biography information for Maggie Throup"} } , "answeringMemberConstituency" : {"_value" : "Erewash"} , "answeringMemberPrinted" : {"_value" : "Maggie Throup"} , "dateOfAnswer" : {"_value" : "2022-04-28", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2022-04-28T11:17:32.237Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2022-04-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Tixagevimab/cilgavimab"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what timeframe the UK Health Security Agency are working to in order to assess the effectiveness of Evusheld against the Omicron variant of covid-19.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"} } , "tablingMemberConstituency" : {"_value" : "Crawley"} , "tablingMemberPrinted" : [{"_value" : "Henry Smith"} ], "uin" : "158930"} , {"_about" : "http://data.parliament.uk/resources/1459980", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459980/answer", "answerText" : {"_value" : "
It has not proved possible to respond to the hon. Member in the time available before Prorogation.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4447", "label" : {"_value" : "Biography information for Maggie Throup"} } , "answeringMemberConstituency" : {"_value" : "Erewash"} , "answeringMemberPrinted" : {"_value" : "Maggie Throup"} , "dateOfAnswer" : {"_value" : "2022-04-28", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2022-04-28T08:55:40.647Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2022-04-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Immunosuppression: Coronavirus"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of immunocompromised individuals who have (a) been hospitalised and (b) died as a result of covid-19 since the MHRA authorised Evusheld for use in the UK.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"} } , "tablingMemberConstituency" : {"_value" : "Crawley"} , "tablingMemberPrinted" : [{"_value" : "Henry Smith"} ], "uin" : "158931"} , {"_about" : "http://data.parliament.uk/resources/1459981", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1459981/answer", "answerText" : {"_value" : "
The information requested is not held centrally as the shielding programme ended in September 2021. The Office for National Statistics\u2019 \u2018Coronavirus and clinically extremely vulnerable people in England\u2019 survey includes information on the behaviours of clinically extremely vulnerable people and their health and wellbeing, which is available at the following link:<\/p>